Olumiant ® (baricitinib) tabletter

För fullständig produktresumé för Olumiant se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Olumiant® ▼ (baricitinib): Jämförelse av läkemedelsinteraktioner med Upadacitinib

Någon direkt jämförande studie mellan baricitinib och upadacitinib har inte genomförts. läkemedelsinteraktionsstudier har utförts separat för varje produkt som en del av deras respektive kliniska utvecklingsprogram.

Baricitinib Drug-Drug Interaction Study Results

The recommended dose is 2 mg once daily in patients taking Organic Anion Transporter 3 (OAT3) inhibitors with a strong inhibition potential, such as probenecid.1

Upadacitinib Drug-Drug Interaction Study Results

A study was conducted to evaluate the effects on the PK of upadacitinib when administered with a strong CYP3A inhibitor (ketoconazole) and a broad CYP inducer (rifampin). Study results included

  • an increase in upadacitinib Cmax by 70% and AUC by 75% when administered with ketoconazole, and

  • a decrease in upadacitnib Cmax by ~50% and AUC by ~60% when administered with multiple doses of rifampin.2

Study authors concluded that a strong CYP3A inhibitor had a weak effect and a broad CYP inducer had a moderate effect on upadacitinib exposure.2

References

1. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Mohamed MF, Jungerwirth S, Asatryan A, et al. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib. Br J Clin Pharmacol. 2017;83(10):2242-2248. https://dx.doi.org/10.1111/bcp.13329.

Glossary

AUC = area under the concentration-time curve

BARI = baricitinib

Cmax = maximum concentration

CYP = cytochrome P450

OAT = organic anion transporter

PK = pharmacokinetic

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M07 25

Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss